Glucose Levels Linked to Maternal Mortality Even in Non-Diabetic Women
|
By LabMedica International staff writers Posted on 02 Jun 2020 |
|
Image: A pre-conception elevated glycated hemoglobin (HbA1c) is associated with a higher risk of severe maternal morbidity or death among women without known diabetes, and below thresholds commonly used to diagnose diabetes mellitus (Photo courtesy of Diabetes.co.uk).
The prevalence of diabetes mellitus (DM) and obesity have rapidly increased worldwide. Serum glycated hemoglobin A1c (HbA1c), expressed as an absolute percent (e.g., 5.5%), offers a convenient and representative measure of average blood glucose control among individuals with DM.
The relation between pre-pregnancy average glucose concentration and a woman’s risk of severe maternal morbidity (SMM) is unknown. A team of scientists have evaluated whether an elevated preconception hemoglobin A1c (HbA1c) is associated with SMM or maternal death among women with and without known pre-pregnancy diabetes mellitus (DM).
A team of Canadian scientists working with those at the University of Toronto (Toronto, ON, Canada) analyzed data in a study of 31,225 women aged 16 through 50 years with a hospital live birth or stillbirth and who had an HbA1c measured within 90 days before conception. 28,075 of the women (90%) did not have a known diagnosis of diabetes mellitus.
The investigators reported that overall, the risk of severe maternal morbidity (SMM) or death from 23 weeks gestation to 6 weeks postpartum was 2.2%. For each 0.5% absolute increase in HbA1c, the relative risk of SMM or death was 1.16 after adjusting for maternal age, multifetal pregnancy, world region of origin, and tobacco/drug dependence. Compared to those with a healthy preconception HbA1c of below 5.8%, the adjusted relative risk of SMM or death was 1.31 in those with a preconception HbA1c of 5.8-6.4% and 2.84 in those with a preconception HbA1c greater than 6.4%. Among women without a diagnosis of diabetes who had an HbA1c over 6.4%, the adjusted relative risk was 3.25.
The authors concluded that women with an elevated HbA1c, preconception or in early pregnancy, had an increased risk of SMM or death. Given its convenience and widespread use, HbA1c testing may also identify those women with preexisting DM at risk of SMM, in a manner similar to its current use in recognizing those at higher risk of fetal anomalies, preterm birth, and preeclampsia. As there is no current recommendation about HbA1c testing in non-diabetic pregnant women, especially those with obesity and/or chronic hypertension, these findings may enhance the knowledge about the benefits of A1c screening in these women. The study was published on May 19, 2020 in the journal PLOS Medicine.
Related Links:
University of Toronto
The relation between pre-pregnancy average glucose concentration and a woman’s risk of severe maternal morbidity (SMM) is unknown. A team of scientists have evaluated whether an elevated preconception hemoglobin A1c (HbA1c) is associated with SMM or maternal death among women with and without known pre-pregnancy diabetes mellitus (DM).
A team of Canadian scientists working with those at the University of Toronto (Toronto, ON, Canada) analyzed data in a study of 31,225 women aged 16 through 50 years with a hospital live birth or stillbirth and who had an HbA1c measured within 90 days before conception. 28,075 of the women (90%) did not have a known diagnosis of diabetes mellitus.
The investigators reported that overall, the risk of severe maternal morbidity (SMM) or death from 23 weeks gestation to 6 weeks postpartum was 2.2%. For each 0.5% absolute increase in HbA1c, the relative risk of SMM or death was 1.16 after adjusting for maternal age, multifetal pregnancy, world region of origin, and tobacco/drug dependence. Compared to those with a healthy preconception HbA1c of below 5.8%, the adjusted relative risk of SMM or death was 1.31 in those with a preconception HbA1c of 5.8-6.4% and 2.84 in those with a preconception HbA1c greater than 6.4%. Among women without a diagnosis of diabetes who had an HbA1c over 6.4%, the adjusted relative risk was 3.25.
The authors concluded that women with an elevated HbA1c, preconception or in early pregnancy, had an increased risk of SMM or death. Given its convenience and widespread use, HbA1c testing may also identify those women with preexisting DM at risk of SMM, in a manner similar to its current use in recognizing those at higher risk of fetal anomalies, preterm birth, and preeclampsia. As there is no current recommendation about HbA1c testing in non-diabetic pregnant women, especially those with obesity and/or chronic hypertension, these findings may enhance the knowledge about the benefits of A1c screening in these women. The study was published on May 19, 2020 in the journal PLOS Medicine.
Related Links:
University of Toronto
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Troponin I Test
Quidel Triage Troponin I Test
New
Respiratory QC Panel
Assayed Respiratory Control Panel
Latest Clinical Chem. News
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
Channels
Molecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read more
Technology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
